Stock Track | Hua Medicine-B Soars 5.14% Intraday on Strong 2025 Earnings and Record Profitability

Stock Track
Mar 27

Hua Medicine-B's stock soared 5.14% during intraday trading on Friday, following the release of its impressive 2025 financial results.

The surge comes after the company announced a historic breakthrough into profitability, with an annual profit of RMB1.11 billion. Its core diabetes drug, dorzagliatin, saw sales volume jump 91% to over 4 million boxes, driving net sales up 93% to RMB 492.9 million. Gross profit surged 125% to RMB 280.4 million, with the margin improving significantly.

Investor sentiment was further buoyed by news of the drug's successful market expansion, including approval in Hong Kong, and the company's optimistic outlook for continued growth and pipeline development in the global diabetes treatment field.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10